Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gemcitabine and paclitaxel for advanced hepatosarcomatoid carcinoma
ChiCTR1800019995Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, gemcitabine and paclitaxel in hepatic sarcomatoid carcinoma (HSC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: objective response rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Rivoceranibgemcitabinepaclitaxel
03
Conditions
hepatic sarcomatoid carcinoma (HSC)
Beyond the preview
Go deeper on ChiCTR1800019995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019995.